---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-274410"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-06-17T21:28:03+00:00"
generated_at: "2026-06-17T21:30:35.299375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acrivon stockholders OK 3M share equity plan increase; elect Tomsicek, Baum

## Summary
- Share reserve increased by 3M shares to 8,606,723; annual 5% auto-increase through 2032 approved.
- Michael Tomsicek and Charles Baum elected Class I directors until 2029 annual meeting.
- PricewaterhouseCoopers ratified as independent auditor for fiscal year 2026.
- Proposals passed with >65% of votes cast; quorum 73.21% of outstanding shares.

## SEC filing metadata
- accession: 0001193125-26-274410
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-06-17T21:28:03+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/acrv-20260617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-274410
- JSON: https://secwatch.observer/filing/0001193125-26-274410.json
- Plain text: https://secwatch.observer/filing/0001193125-26-274410.txt

## Key facts
- Shareholder Votes
  Acrivon Therapeutics, Inc. shareholders approved Approval of the Amendment and Restatement of the Company's 2022 Equity Incentive Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: Votes were cast as follows: For Against Abstain Broker Non-Votes 20,546,400 3,757,400 104,757 6,928,436
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm
- Shareholder Votes
  Acrivon Therapeutics, Inc. shareholders approved Election of Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. as Class I Directors.
  - Proposal: director election
  - Outcome: passed
  source text: Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 24,020,408 1,229,385 6,087,200 Charles Baum, M.D., Ph.D. 23,657,074 1,592,719 6,087,200
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm
- Shareholder Votes
  Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm.
  - Proposal: auditor ratification
  - Outcome: passed
  source text: Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/0001193125-26-274410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.